The First Case of COVID-19 in the US Treated with Remdesivir Was in late January – Two Weeks Later China Was Mass Producing the Drug – The Firm Gilead Sciences and Dr. Fauci Are In the Middle
The first known case of COVID-19 showed up in the US in Washington state on January 19, 2020. The individual had traveled to visit family in Wuhan, China, and had returned on the 15th. The patient was immediately placed under surveillance and after declining health, he was finally given a drug being developed, remdesiver
Soon after treatment the individual recovered.
he Washington State patient was lucky that the clinic that he first attended provided his samples to the CDC. It’s certainly unique that the patient was recommended remdesivir for treatment. He was then advertised as the first COVID-19 infected patient to recover from remdesivir.
By mid-February a Chinese company started mass- producing remdesivir:
On Feb. 12, 2020 – that is correct, Feb. 12 – 10 days after Trump initiated the China travel ban, Bloomberg reported:
“A Chinese drugmaker said it has started mass-producing an experimental drug from Gilead Sciences that has the potential to fight the novel coronavirus, as China accelerates its effort to find a treatment for the widening outbreak.
Then in late February, a study began in Nebraska, to evaluate remdesivir (which all sounds a$$ backwards):
A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) has begun at the University of Nebraska Medical Center (UNMC) in Omaha. The trial regulatory sponsor is the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. This is the first clinical trial in the United States to evaluate an experimental treatment for COVID-19, the respiratory disease first detected in December 2019 in Wuhan, Hubei Province, China.
Looking back, it’s curious how the doctors in Washington state became aware of the use of remdesivir for COVID-19. What information did they receive that would lead them to try this relatively unknown drug? Then how could the drug begin being mass-produced in China before trials even occurred in the US?
Perhaps the answer is related to the firm that produces remdesivir – Gilead Sciences. It’s mission is – “To advance therapeutics against life-threatening diseases worldwide”. Gilead is a also a large company that spends millions in its lobbying efforts annually:
And just who, or what is Gilead Sciences? Gilead is partnered with Wuxi AppTec, an international pharmaceutical, biopharmaceutical and medical device company. According to Wikipedia, “The company covers the development cycle through five core operations, including small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics.” And where, you may ask, is the company located? Wuxi AppTec was begun in Shanghai by Dr. Gi Li now with facilities also in Wuxi City and Suzhou, China, as well as facilities in St. Paul, Minnesota, Philadelphia and Atlanta. Wuxi AppTec is owned in part by none other than America’s own – George Soros
https://twitter.com/gatewaypundit/status/1260579551618441224
https://www.thegatewaypundit.com/2020/05/first-case-covid-19-us-treated-remdesivir-late-january-two-weeks-later-china-mass-producing-drug-firm-gilead-sciences-dr-fauci-middle/